Bellicum Announces Publication in The New England Journal of Medicine ... MarketWatch (press release) CaspaCIDe(TM) DLI is a donor lymphocyte infusion administered following a hematopoietic stem cell transplant, in which the safety switch may be activated to resolve graft-versus-host disease (GVHD). For more information, visit www.bellicum.com . |
